Dashboard
Manage Tickers

BCRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

td-cowen-reinstates-buy-on-biocryst-pharma-announces-30-price-target
TD Cowen Reinstates Buy on BioCryst Pharma...
10/15/2025 14:15:07

TD Cowen analyst Stacy Ku reinstates BioCryst Pharma (NASDAQ:BCRX) with a Buy and announces $30 price target.

cantor-fitzgerald-maintains-overweight-on-biocryst-pharma-raises-price-target-to-26
Cantor Fitzgerald Maintains Overweight on ...
10/15/2025 14:11:32

Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overweight and raises the price ta...

jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-27
JMP Securities Maintains Market Outperform...
10/15/2025 11:21:33

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

needham-maintains-buy-on-biocryst-pharma-raises-price-target-to-20
Needham Maintains Buy on BioCryst Pharma, ...
10/15/2025 10:00:17

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $17 to $20.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 17:06:11

biocryst-says-astria-therapeutics-700-million-deal-gives-perfect-second-product-candidate
BioCryst Says Astria Therapeutics $700 Mil...
10/14/2025 16:20:52

BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit...

trading-halt-halt-status-updated-at-71500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:15:...
10/14/2025 11:15:04

Core News & Articles
BioCryst to Acquire Astria Therapeutics fo...
10/14/2025 11:02:17

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
10/14/2025 10:55:04

biocryst-pharmaceuticals-and-biocryst-ireland-entered-into-a-trademark-license-agreement
BioCryst Pharmaceuticals And Biocryst Irel...
10/01/2025 13:37:47

-SEC Filing

ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder
Ionis Pharma Wins FDA Nod For First RNA-Ta...
08/21/2025 18:24:53

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch pat...

needham-maintains-buy-on-biocryst-pharma-maintains-17-price-target
Needham Maintains Buy on BioCryst Pharma, ...
08/04/2025 22:11:09

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $17 price target.

biocryst-pharma-maintains-fy25-outlook-for-global-net-orladeyo-revenue-between-580m-and-600m
BioCryst Pharma Maintains FY25 Outlook For...
08/04/2025 11:05:04

Financial Outlook for 2025The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580...

biocryst-pharma-q2-eps-002-misses-004-estimate-sales-163353m-beat-149530m-estimate
BioCryst Pharma Q2 EPS $0.02 Misses $0.04 ...
08/04/2025 11:01:10

BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0....

Core News & Articles
Earnings Scheduled For August 4, 2025
08/04/2025 08:32:29

earnings-outlook-for-biocryst-pharma
Earnings Outlook For BioCryst Pharma
08/01/2025 19:05:13

biocryst-pharmaceuticals-president-and-ceo-jon-stonehouse-will-retire-on-december-31-the-company-has-appointed-charlie-gayer-currently-the-companys-chief-commercial-officer-as-the-next-president-effective-august-1-and-next-ceo-effective-january-1-2026
BioCryst Pharmaceuticals' President And CE...
07/31/2025 11:17:29

biocryst-pharmaceuticals-appoints-babar-ghias-as-chief-financial-officer-and-head-of-corporate-development
BioCryst Pharmaceuticals Appoints Babar Gh...
07/07/2025 11:02:09

b-of-a-securities-maintains-buy-on-biocryst-pharma-raises-price-target-to-15
B of A Securities Maintains Buy on BioCrys...
07/01/2025 13:44:30

B of A Securities analyst Tazeen Ahmad maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the price target from $...

rbc-capital-reiterates-outperform-on-biocryst-pharma-maintains-13-price-target
RBC Capital Reiterates Outperform on BioCr...
06/30/2025 14:04:24

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $13 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION